Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - medicinska sredstva za jednokratnu upotrebu

Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - medicinska sredstva za jednokratnu upotrebu

Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"adoc" d.o.o. beograd predstavniŠtvo u podgorici - in vitro dijagnostička medicinska sredstva

Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"adoc" d.o.o. beograd predstavniŠtvo u podgorici - in vitro dijagnostička medicinska sredstva

Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"farmont m.p." d.o.o. za proizvodnju, promet i usluge, export-import danilovgrad - medicinska sredstva za jednokratnu upotrebu

Uniunea Europeană - croată - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotska sredstva - duoplavin je indiciran za sekundarnu prevenciju aterotrombotskih događaja u bolesnika odraslih koji već uzimaju i klopidogrel i acetilsalicilnu kiselinu (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. za više informacija, molimo pogledajte odjeljak 5.

Muntenegru - croată - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

druŠtvo za proizvodnju, posredovanje i promet "urion" d.o.o. podgorica - medicinska sredstva za jednokratnu upotrebu

Uniunea Europeană - croată - EMA (European Medicines Agency)

teva b.v. - clopidogrel (as hydrogen sulfate) - myocardial infarction; acute coronary syndrome; peripheral vascular diseases; stroke - antitrombotska sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. odraslih pacijenata oboljelih od akutne коронарным sindroma:bez elevacije segmenta st akutna koronarna sindrom (nestabilna angina, ili ne-q-инфарктом miokarda), uključujući i bolesnike koji su patili ugradnje stenta nakon чрескожного koronarne intervencije, u kombinaciji s ацетилсалициловой kiselinom (ask). porastom segmenta st akutni infarkt miokarda, u kombinaciji s ask u liječenju pacijenata koji imaju pravo na thrombolytic terapije. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje антагонистами vitamina k (ВКА) i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.

Uniunea Europeană - croată - EMA (European Medicines Agency)

mylan ireland limited - rivaroksaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotska sredstva - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Uniunea Europeană - croată - EMA (European Medicines Agency)

actavis group ptc ehf - reteplaza - infarkt miokarda - antitrombotska sredstva - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.